Tae Min Kim et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10(12), 1736-1744 (2015-10-17)
AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. However, acquired resistance to AZD9291 is inevitable. In this